Alumis (ALMS) Profit After Tax (2023 - 2026)
Alumis' (ALMS) quarterly Profit After Tax came in at -$142.4 million in Q2 2026, down 339.99% year-over-year from $59.4 million in Q2 2025, and down 51.37% quarter-over-quarter from -$94.1 million in Q4 2025.
Analysis
Alumis (ALMS) Profit After Tax (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Profit After Tax for 4 consecutive years, with -$142.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Profit After Tax fell 339.99% year-over-year to -$142.4 million in Q2 2026; TTM through Jun 2026 was -$288.0 million, a 18.49% increase from a year earlier, with the FY2025 full-year figure at -$475.1 million, down 20.53% from the prior year.
- Profit After Tax was -$142.4 million for Q2 2026 at Alumis, down from -$94.1 million in the prior quarter.
- Over five years, Profit After Tax peaked at $59.4 million in Q2 2025 and troughed at -$172.1 million in Q4 2024.
- A 4-year average of -$77.2 million and a median of -$75.3 million in 2024 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax jumped 205.03% in 2025 and slumped 339.99% in 2026, its largest moves.
- Over 4 years, Profit After Tax stood at -$39.3 million in 2023, then sank by 337.79% to -$172.1 million in 2024, then jumped by 45.31% to -$94.1 million in 2025, then tumbled by 51.37% to -$142.4 million in 2026.
- The last three Profit After Tax figures came in at -$142.4 million (Q2 2026), -$94.1 million (Q4 2025), and -$110.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Alumis | 1.27 Bn | 765.76 Mn | - | -142.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -142.44 Mn |
| Dec 31, 2025 | -94.10 Mn |
| Sep 30, 2025 | -110.80 Mn |
| Jun 30, 2025 | 59.35 Mn |
| Mar 31, 2025 | -98.96 Mn |
| Dec 31, 2024 | -172.05 Mn |
| Sep 30, 2024 | -141.67 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -49.85 Mn |
| Dec 31, 2023 | -39.30 Mn |
| Sep 30, 2023 | -43.40 Mn |
| Jun 30, 2023 | -36.29 Mn |